Collagen News and Research

Latest Collagen News and Research

MiMedx Group completes corporate and technology branding initiative

MiMedx Group, Inc. announced today that it has completed its corporate and technology branding initiative. In concert with its branding initiative, the Company also announced that it has recently launched an updated website.

25 Feb 2010

Platelet function tests may predict heart attack, says study

An analysis of six tests that are used to measure platelet function and help gauge the effectiveness of antiplatelet drugs for patients undergoing a cardiac procedure such as a coronary stent implantation found that only three of the tests were associated with a modest ability to predict outcomes such as heart attack or death, according to a study in the February 24 issue of JAMA.

25 Feb 2010

SSRIs exhibit anti-inflammatory effects and may provide drug development opportunities for RA

A new study found that fluoxetine (Prozac-) and citalopram (Celexa-) treatment significantly inhibited disease progression of collagen-induced arthritis (CIA) in mice. Research led by Sandra Sacre, Ph.D. from the Brighton and Sussex Medical School (BSMS) in the UK studied the anti-arthritic potential of these drugs, known as selective serotonin reuptake inhibitors (SSRIs), most commonly used to treat depression.

25 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

Valensa International enters into license agreement with Biova for BiovaFlex ingredient

Valensa International (Eustis, FL USA) announced today that it has entered into a license agreement with Biova, LLC (Johnston, Iowa USA) that will allow Valensa to include the patented BiovaFlex(TM) water-soluble egg shell membrane ingredient in a proprietary new series of formulated joint health products.

19 Feb 2010

HealthTrust Purchasing Group signs 3-year vascular graft procurement contract with MAQUET Cardiovascular

MAQUET Cardiovascular, LLC, a leading provider of cardiovascular technologies, announced today that it has signed a three year contract with HealthTrust Purchasing Group, LP to provide woven and knitted textile vascular grafts to the HealthTrust membership. The contract includes the HEMASHIELD product line and other vascular grafts, which are used to surgically repair or replace damaged blood vessels, including the aorta.

18 Feb 2010

PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging.

11 Feb 2010

Glissandra Skincare signs first distribution agreement with Enchanted Meadow

Glissandra Skincare™ Inc., dedicated to the research, development, and manufacturing of anti-aging skincare products, announced it has signed its first distributorship agreement granting Enchanted Meadow the rights to distribute Glissandra to its more than 2000 spa and gift industry retailers throughout the US and Canada.

10 Feb 2010

Cynosure settles patent infringement lawsuit against CoolTouch

Cynosure, Inc., developer of the award-winning Smartlipo™ LaserBodySculpting(SM) procedure for minimally invasive removal of fat, and its largest shareholder, El.En. S.p.A, today announced a settlement of their patent infringement lawsuit against CoolTouch, Inc. Cynosure and El.En. alleged that CoolTouch's 1320 nm CoolLipo™ laser system infringed on El.En.'s U.S. Patent No. 6,206,873 (the 873 patent) licensed to Cynosure, which covers laser technology to remove subcutaneous fat.

9 Feb 2010

Thymosin β4 exhibits potential as new therapeutic agent for liver failure due to chronic HBV infection

REGENERX BIOPHARMACEUTICALS, INC. announced today that researchers have correlated Tβ4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin β4 levels were significantly lower in patients with chronic hepatitis B infection and that the magnitude of the reduction of thymosin β4 was closely related to the severity of the hepatic injury and to patient death. Since patients with higher Tβ4 levels survived the disease, changes in Tβ4 values could reflect outcome in some liver failure patients.

9 Feb 2010

Tβ4 may help treat skeletal muscle disease in Duchenne muscular dystrophy

REGENERX BIOPHARMACEUTICALS, INC. announced today that a research team in Washington, D.C. has found that dystrophin-deficient Mdx mice, treated twice a week for six months with Tβ4, showed a significant increase in skeletal muscle regenerating fibers compared to untreated mice. No effects related to muscle function or fibrosis and no adverse reactions were observed in the mice.

6 Feb 2010

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration (FDA) has approved Xiaflex, a new drug to treat Dupuytren's contracture (or disease) that was discovered and developed by Marie A. Badalamente, Ph.D., and Lawrence C. Hurst, M.D., in the Department of Orthopaedics at Stony Brook University Medical Center.

4 Feb 2010

BioSpecifics Technologies' XIAFLEX receives FDA approval

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that the U.S. Food and Drug Administration (FDA) has approved XIAFLEX™, a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord.

3 Feb 2010

Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement

Suneva Medical, a privately-held aesthetic medical device company, today announced that two clinical studies suggest Artefill may be a safe, effective, long-term treatment option for age-related and HIV lipoatrophy patients.

3 Feb 2010

Xiaflex receives FDA approval for treatment of Dupuytren's contracture

The U.S. Food and Drug Administration today approved Xiaflex (collagenase clostridium histolyticum) as the first drug to treat a progressive hand disease known as Dupuytren's contracture, which can affect a person's ability to straighten and properly use their fingers.

2 Feb 2010

VHGI sells Secure eHealth to WNDM

VirtualHealth Technologies, Inc. announced today that it has completed the sale of secure data and messaging provider, Secure eHealth, LLC, along with certain other technology assets to Wound Management Technologies, Inc. as previously announced in the January 11 press release. In addition to the sale of Secure eHealth, VHGI has also transferred all of the intellectual property assets of the real-time prescription drug monitoring business conducted by its subsidiary, VPS Holdings, LLC to Wound Management.

2 Feb 2010

Researchers design bioactive nanomaterial that promotes cartilage growth

Northwestern University researchers are the first to design a bioactive nanomaterial that promotes the growth of new cartilage in vivo and without the use of expensive growth factors. Minimally invasive, the therapy activates the bone marrow stem cells and produces natural cartilage.

1 Feb 2010

Salient Surgical Technologies, Exeter Hospital and Moffitt Cancer Center donate medical supplies to Haiti

Salient Surgical Technologies of Portsmouth, New Hampshire, has partnered with Exeter Hospital in Exeter, New Hampshire and Moffitt Cancer Center in Tampa, Florida, to donate equipment and supplies for a mission to aid victims of the January 12 earthquake in Haiti.

30 Jan 2010

RTI Biologics donates Matrix HD to treat eight-year-old with recessive dystrophic EB

RTI Biologics Inc. (RTI), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated a sterilized dermis allograft, Matrix HD™, to treat an eight-year old patient with a rare skin disease called recessive dystrophic epidermolysis bullosa (EB).

29 Jan 2010

Aubrey receives FDA clearance to market bioengineered wound dressings in U.S.

Aubrey Inc., an advanced wound care company, announced it has received clearance from the US Food and Drug Administration (FDA) to market the AWBAT Plus product line in the United States.

28 Jan 2010